Muralidharan Anbalagan, Assistant Professor, at Tulane University in New Orleans.
The findings were presented at ENDO 2019, the Endocrine Society's annual meeting in New Orleans.
For the preliminary study, the team created a mouse model of bone metastatic breast cancer. They injected oestrogen receptor-positive human breast cancer cells, which have a low propensity to grow in bones, into the tibia (shinbone) of female mice.
Like humans, mice produced a strong night-time circadian melatonin signal, shown to produce strong anti-cancer actions and for promoting sleep.
While one group of mice was kept in the light for 12 hours each day, the other group of three mice in the dark for 12 hours. Another group spent 12 hours in light, followed by 12 hours in dim light at night.
X-ray images showed that mice exposed to a light or dim light cycle had much larger tumours and increased bone damage compared with mice kept in a standard light/dark cycle, he noted.
"Our research identified the importance of an intact nocturnal circadian melatonin anti-cancer signal in suppressing bone-metastatic breast tumour growth," Anbalagan said.